GPCR Structure Therapeutics Inc.

CIK 0001888886 22 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 22

Latest filing May 7, 2026, 7:59 PM ET

Top materiality 0.90

Event mix other_material ×9 · earnings ×9 · leadership ×3

Sentiment 9 pos · 0 neg · 13 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for GPCR

Highest-materiality recent filing

Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

May 7, 2026, 7:59 PM ET other material materiality 0.90 positive item 1.01 item 2.02 item 8.01 item 9.01 ◈ Earnings Releases◈ Material Agreements

Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.
Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.

Read filing →

May 7, 2026, 7:59 PM ET other material materiality 0.90 positive item 1.01 item 2.02 item 8.01 item 9.01 ◈ Earnings Releases◈ Material Agreements

Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.
April 15, 2026, 7:59 PM ET leadership materiality 0.65 positive item 5.02 item 7.01 item 9.01

Structure Therapeutics appoints Matthew Lang as COO and General Counsel

Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.
March 16, 2026, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks

Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.
February 26, 2026, 6:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01

Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2

Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.
January 5, 2026, 6:59 PM ET other material materiality 0.85 positive item 1.01 ◈ Material Agreements

Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront

Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.
December 10, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Structure Therapeutics launches $650M follow-on offering of ADSs and pre-funded warrants

Gross proceeds ~$650M from 8.46M ADSs at $65.00 and 1.54M pre-funded warrants at $64.9999.
December 8, 2025, 6:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.
November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025

Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.
August 6, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025

Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.
February 27, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M

ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.
December 17, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025

ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.
November 13, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study

Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.
September 17, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change

Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession

Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.
August 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024

Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.
June 3, 2024, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290

GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.
June 3, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Structure Therapeutics updates risk factors and GLP-1 agonist market data in 8-K filing

Updated disclosure: six GLP-1R agonists generated ~$35.9B in 2023 sales, projected to reach $85.9B by 2027.
May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024

Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.
March 8, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024

Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.

Executive changes

Departed

Mark Bach

Chief Medical Officer

GPCR · Structure Therapeutics Inc.

Effective: 2024-09-18
Filed: September 17, 2024, 7:59 PM ET

On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).

Appointed

Angus Russell

Class I director

GPCR · Structure Therapeutics Inc.

Effective: 2024-08-26
Filed: August 27, 2024, 7:59 PM ET

appointed Angus Russell to the Board, effective August 26, 2024.

Earnings & guidance

2025-FY EPS reported -$0.80 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

9 positive 0 negative 13 neutral

source · GPCR on sec.gov